Miglustat
Contents
Description
Miglustat is a small molecule iminosugar that acts as a glucosylceramide synthase inhibitor, reducing the synthesis of glycosphingolipids. It is used as substrate reduction therapy for lysosomal storage disorders affecting sphingolipid metabolism. The drug provides an alternative treatment approach when enzyme replacement therapy is not suitable or available.
Indications & Therapeutic Use
Gaucher disease type 1, Niemann-Pick disease type C, disorders of sphingolipid biosynthesis
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Miglustat — GNH India
50 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | miglustat |
| Brands | 1 brand available |
| Active Ingredient | miglustat |
| Drug Class | Gaucher disease type 1 |
| Manufacturer | Actelion Pharmaceuticals |
| Dosage Forms | Oral capsule, 100mg |
| Medical Code | A16AX06 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00358150 |
| Countries | 9 countries |